Thorne SH - Search Results

1

Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.

Wang LC, Lynn RC, Cheng G, Alexander E, Kapoor V, Moon EK, Sun J, Fridlender ZG, Isaacs SN, Thorne SH, Albelda SM. Wang LC, et al. Among authors: thorne sh. Mol Ther. 2012 Apr;20(4):736-48. doi: 10.1038/mt.2011.228. Epub 2011 Oct 18. Mol Ther. 2012. PMID: 22008913 Free PMC article.

2

The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?

Thorne SH, Bartlett DL, Kirn DH. Thorne SH, et al. Curr Gene Ther. 2005 Aug;5(4):429-43. doi: 10.2174/1566523054546215. Curr Gene Ther. 2005. PMID: 16101516 Review.

3

Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy.

Thorne SH, Tam BY, Kirn DH, Contag CH, Kuo CJ. Thorne SH, et al. Mol Ther. 2006 May;13(5):938-46. doi: 10.1016/j.ymthe.2005.12.010. Epub 2006 Feb 8. Mol Ther. 2006. PMID: 16469543 Free article.

4

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, Roh MS, Je JE, Yoon JH, Thorne SH, Kirn D, Hwang TH. Kim JH, et al. Among authors: thorne sh. Mol Ther. 2006 Sep;14(3):361-70. doi: 10.1016/j.ymthe.2006.05.008. Mol Ther. 2006. PMID: 16905462 Free article.

5

Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.

Thorne SH, Contag CH. Thorne SH, et al. Gene Ther. 2008 May;15(10):753-8. doi: 10.1038/gt.2008.42. Epub 2008 Mar 20. Gene Ther. 2008. PMID: 18356814 Review.

6

Oncolytic vaccinia virus: from bedside to benchtop and back.

Thorne SH. Thorne SH. Curr Opin Mol Ther. 2008 Aug;10(4):387-92. Curr Opin Mol Ther. 2008. PMID: 18683104

7

Design and testing of novel oncolytic vaccinia strains.

Thorne SH. Thorne SH. Methods Mol Biol. 2009;542:635-47. doi: 10.1007/978-1-59745-561-9_32. Methods Mol Biol. 2009. PMID: 19565925

8

Synergistic interaction between oncolytic viruses augments tumor killing.

Le Boeuf F, Diallo JS, McCart JA, Thorne S, Falls T, Stanford M, Kanji F, Auer R, Brown CW, Lichty BD, Parato K, Atkins H, Kirn D, Bell JC. Le Boeuf F, et al. Mol Ther. 2010 May;18(5):888-95. doi: 10.1038/mt.2010.44. Epub 2010 Mar 16. Mol Ther. 2010. PMID: 20234341 Free PMC article.

9

Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy.

Thorne SH, Liang W, Sampath P, Schmidt T, Sikorski R, Beilhack A, Contag CH. Thorne SH, et al. Mol Ther. 2010 Sep;18(9):1698-705. doi: 10.1038/mt.2010.140. Epub 2010 Jul 6. Mol Ther. 2010. PMID: 20606649 Free PMC article.

10

Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1.

Huang B, Sikorski R, Kirn DH, Thorne SH. Huang B, et al. Among authors: thorne sh. Gene Ther. 2011 Feb;18(2):164-72. doi: 10.1038/gt.2010.121. Epub 2010 Aug 26. Gene Ther. 2011. PMID: 20739958

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Search Page

Filters